Thyroid cancer is the most common endocrine malignancy, constituting 0.1%--0.2% of all cancers in India with an age-adjusted incidence of 1 per 100,000 in males and 1.8 per 100,000 in females \[[@b1-jptm-2017-08-04]\]. As per the latest three-year report of 27 population based cancer registries from 2012 to 2014 issued by the National Cancer Registry Program, the incidence was particularly high among females of Papumpare District in Arunachal Pradesh (age adjusted rate 20.7 per 100,000 population), followed by Thiruvananthapuram (13.3) and Kollam Districts (12.0) in Kerala \[[@b2-jptm-2017-08-04]\].

Thyroid cancers most commonly present as a solitary thyroid nodule. The consensus guidelines from the Endocrine Society of India published a summary of current medical evidence for thyroid nodule management and optimized the guidelines for the clinical practice setting in India \[[@b3-jptm-2017-08-04]\]. It includes a strong recommendation (Level A) for evaluation of all thyroid nodules \> 1 cm, including both palpable and radiologically distinct non-palpable nodules \[[@b3-jptm-2017-08-04]\]. Prevalence of palpable nodules in India is about 12.2% \[[@b4-jptm-2017-08-04]\]. India being an endemic area for goiter due to iodine deficiency, it is important to differentiate benign thyroid nodules from malignant ones.

Numerous studies have demonstrated that fine-needle aspiration cytology (FNAC) is a valid procedure for evaluation of thyroid nodules in adults and pediatric population. The role of FNAC is increasing in recent years in management and risk assessment of thyroid nodules.

Cytological evaluation of thyroid swellings is a rapid, easy and inexpensive diagnostic procedure which is widely used as a screening tool. It helps in triaging the patients into candidates for surgical or conservative management. However, the technique has its own shortcomings mainly due to interobserver and intraobserver variability, especially in indeterminate cases. In addition, there is also a lack of uniformity in the reporting systems used, which vary not only from country to country but also from laboratory to laboratory and even among individuals working at the same laboratory. This hampers accurate interpretation by the clinician, thus affecting patient management. To address this common issue, the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was introduced based upon the proceedings of "The NCI Thyroid Fine Needle Aspiration State of the Science Conference" held in Bethesda, Maryland, in 2007 \[[@b5-jptm-2017-08-04]\]. TBSRTC encompasses six thyroid cytology categories, with each category having an implied cancer risk and the best modality of management \[[@b5-jptm-2017-08-04]\].

Here we review the available Indian literature on the status of thyroid aspiration cytology in India along with a meta-analysis of the reviewed data. We performed an extensive literature search in PubMed and Google Scholar databases using the following keywords: "India," "thyroid," "cytology," "cytopathology," "audit," "cytology-histology correlation," "the Bethesda system," "TBSRTC," and "FNAC." Those reports in which a recognizable classification system was used to categorize thyroid cytology smears were included. Case reports and case series were excluded. Cross-references of the selected articles were also checked to look out for additional studies. For meta-analysis, publications with available histopathological correlation were evaluated. The publications which had not used TBSRTC but had used a four or higher-tier system (including "unsatisfactory" category) were reclassified to fit into one of the TBSRTC categories. Hence, "indeterminate cases" were categorized as "atypia of undetermined significance/follicular lesion of undetermined significance" (AUS/FLUS, category III), while "follicular neoplasm," "follicular patterned lesion" and "Hurthle cell lesion/neoplasm" were classified as "follicular neoplasm/suspicious for a follicular neoplasm" (category IV). Wherever possible, the risk of malignancy (ROM) and the risk of neoplasm (RON) were calculated \[[@b6-jptm-2017-08-04]\]. Reports with just two categories (benign and neoplastic) besides unsatisfactory and those using histopathological terminologies for imparting cytological diagnoses were not included in the meta-analysis. Papers just providing statistical measures of performance (sensitivity, specificity, negative and positive predictive values) of cytology in comparison with histopathology but not providing details of the histopathological diagnoses were also excluded from the meta-analysis. It should be noted that approximately half of the analyzed articles were published in non-PubMed indexed journals, which may raise an issue regarding quality of the publications. As per our evaluation, studies employed for this review contained sufficient amount of raw or processed data, and hence were eligible for inclusion.

BRIEF HISTORY OF THYROID FINE-NEEDLE ASPIRATION IN INDIA
========================================================

FNAC was first used for cytological diagnosis in 1930s \[[@b7-jptm-2017-08-04]\]; however, the method has been widely used after 1952 \[[@b8-jptm-2017-08-04]\]. In India, FNAC has been introduced in early 1970s \[[@b9-jptm-2017-08-04]\]. First publication on FNAC appeared in 1975 by Gupta *et al*. \[[@b10-jptm-2017-08-04]\], which was published in the Indian Journal of Cancer. Needle biopsy of the thyroid had been attempted for the first time in 1965 in India \[[@b11-jptm-2017-08-04]\], whereas the first paper on FNAC of the thyroid dates back to 1987 by Rege *et al*. \[[@b12-jptm-2017-08-04]\] Needle aspiration was initially started without any guidance. Later, with the advent of interventional radiology, the lesional localization was improved. Ultrasound-guided fine-needle aspiration (FNA) is a widely-acclaimed technique in investigating thyroid nodules/lesions. Approximately 50 reports so far have been published based on the Bethesda system and otherwise fulfilling our abovementioned criteria ([Table 1](#t1-jptm-2017-08-04){ref-type="table"}) \[[@b13-jptm-2017-08-04]-[@b63-jptm-2017-08-04]\].

Most studies reclassified cases as per TBSRTC, and compared their distribution data and the ROM in each of the categories ([Table 2](#t2-jptm-2017-08-04){ref-type="table"}) \[[@b13-jptm-2017-08-04]-[@b63-jptm-2017-08-04]\]. Few compared diagnostic accuracy and inter-observer variation of previously used classification systems with TBSRTC. Old classification systems have been used in few of the studies which evaluated sensitivity and specificity of thyroid cytology in accurate diagnoses.

OPERATOR OF THYROID FINE-NEEDLE ASPIRATION
==========================================

Review of available literature in India and our personal experience suggest that most blind, palpation guided FNAs of thyroid are done by pathologists, whereas clinicians or radiologists perform the FNAC under image guidance and leave the interpretation to pathologists. Although an occasional publication does provide evidence of at least some cases being aspirated by surgical medical officers, by-and-large, palpation-guided thyroid FNA is mostly performed by cytopathologists and ultrasound-guided aspiration by radiologists \[[@b60-jptm-2017-08-04]\].

In India, palpation-guided FNA appears to be the most commonly used technique, probably being more cost-effective ([Table 1](#t1-jptm-2017-08-04){ref-type="table"}). Ultrasound-guided FNA is usually reserved for small or deep-seated poorly palpable nodules. It is also preferable to use ultrasound guidance to aspirate predominantly cystic lesions and for repeat aspiration of a previously non-diagnostic/unsatisfactory aspirate. Only a few centers are using the ultrasound-guided technique for all patients irrespective of the type of the thyroid nodule ([Table 1](#t1-jptm-2017-08-04){ref-type="table"}) \[[@b34-jptm-2017-08-04],[@b58-jptm-2017-08-04]\].

Interpretation can be done immediately after procedure at the site of FNA or later in the laboratory after staining of aspiration smears. Without rapid on-site evaluation (ROSE), a significant subset of thyroid FNAs are diagnosed inadequate/unsatisfactory for interpretation, which potentially leads to repeat aspirations and additional procedures. The basic purpose of ROSE is to increase the adequacy rate, diagnostic yield, and accuracy of the procedure. Systemic reviews and meta-analysis showed significant reduction in inadequacy rate of thyroid FNAs with ROSE \[[@b64-jptm-2017-08-04],[@b65-jptm-2017-08-04]\]. Acquisition of ROSE in routine practice depends upon the infrastructure of the institute which includes availability of manpower, location of the procedure room, case volume, and resources. In our institute, ROSE is offered to all thyroid FNAs under guidance, and it is performed by cytopathologists. Studies on comparison analysis of adequacy assessment of thyroid FNA with and without ROSE were not found in Indian literature. We believe ROSE is practiced only in a few academic institutions in India.

CYTOTECHNICIAN TRAINING PROGRAM AND QUALITY CONTROL IN INDIA
============================================================

The Indian Academy of Cytologists (<http://www.cytoindia.com>) conducts examination for cytotechnicians and cytotechnologists. There are few centers which run cytotechnician and cytotechnologist training programs for certification. Cytotechnologists work as cytoscreeners; however, in India only limited institutions have cytoscreeners. Their work allocation depends upon the institutional work requirement and administration policies.

The External Quality Assurance Programme of the Indian Academy of Cytologists is aimed to maintain and monitor the quality of reporting on all cytopathology specimens, in which over 100 cytopathology laboratories from all over the India participate for FNA, exfoliative specimens and cervical smears. In terms of thyroid FNA, only straightforward diagnoses (such as lymphocytic thyroiditis or carcinomas) are assessed and so TBSRTC is not strictly followed, unlike cervical smears where it is mandatory to diagnose lesions according to the Bethesda classification (personal communication with Prof. Radhika Srinivasan, Postgraduate Institute of Medical Education and Research, Chandigarh, India).

PREPARATION AND STAINING OF THYROID CYTOLOGY SAMPLES
====================================================

The needles used in thyroid FNA vary in size from 21G to 28G, with or without aspiration for fine needle aspiration cytology and fine needle capillary sampling, respectively ([Table 1](#t1-jptm-2017-08-04){ref-type="table"}). The most commonly used needle was 23G followed by 24G in published studies. Since the thyroid is a highly vascular organ, and given the risk of hemorrhagic complications, it is advisable to use a small-bore needle (25--27 gauge). The unstained smear may then be visually evaluated for tissue fragments and/or colloid, and if required, a larger bore needle may be used for subsequent aspirations \[[@b5-jptm-2017-08-04],[@b66-jptm-2017-08-04]\]. Larger diameter needles are also preferable for draining thick colloid \[[@b5-jptm-2017-08-04]\].

Most institutes use direct smears in which the material is smeared onto the glass slide and either kept air-dried for Romanowsky stains (May-Grünwald-Giemsa, Leishman, Giemsa) stain or wet-fixed with common fixatives (95% ethyl alcohol, 95% methanol, 95% isopropyl alcohol, or a solution of ether and 95% alcohol) for Papanicolaou and/or hematoxylin and eosin stain (H&E). Papanicolaou and H&E stains help in characterization of nuclear features whereas Romanowsky stains better define cytoplasmic characteristics. In case of cystic nodules, aspirated fluid is centrifuged and smears are prepared from the sediment. Most cytopathologists in India use a combination of Romanowsky and Papanicolaou stains. However, H&E is preferred in a few institutions due to its cost effectiveness and better familiarity of the stain from surgical pathology.

Liquid-based cytology (LBC) is another adjunctive technique in thyroid FNA which is associated with better preservation of cellular details. It removes obscuring hemorrhage, cellular debris and inflammatory cells to a large extent from the background. Keyhani *et al*. \[[@b67-jptm-2017-08-04]\] have compared conventional, cell block and LBC preparations in a cohort of 100 patients with thyroid nodules. While a significant percentage (87%) of cases yielded informative results using LBC method, only 69% of the samples processed for cell blocks were informative. Both techniques had almost equal sensitivity (95% for LBC vs 96% for cell block), but the specificity of LBC (31%) was reported to be higher than that of the cell block (24%). It has been suggested that LBC may be used as a supplementary technique to conventional smears to improve the diagnostic yield of thyroid aspiration cytology. In a more recent study by Prasad *et al*. \[[@b68-jptm-2017-08-04]\], LBC slides from 41 cases of thyroid swellings (23 nodular colloid goiter, 14 thyroiditis, and 4 carcinoma) were assessed and compared with conventional smears. Importantly, the authors cautioned against the regular use of LBC in thyroid cytology. While the amount of background colloid was reported to be significantly diminished, they found nuclear features (grooves and pseudoinclusions) of papillary thyroid carcinoma less forthcoming on LBC. Another study evaluated 18 cases of thyroid swellings (10 colloid goiter, four thyroiditis, and four carcinoma cases) by LBC and compared the results with conventional smears \[[@b69-jptm-2017-08-04]\]. While the technique was not found to be of much use in benign thyroid diseases, it was beneficial in diagnosis of neoplastic lesions. However, the small number of cases evaluated precludes any definite interpretation. To conclude, data reported from Indian institutions suggest that LBC may be used as an adjunct method but cannot replace conventional smears in thyroid cytology.

THYROID CYTOLOGY REPORTING SYSTEMS
==================================

Reporting of thyroid aspirate smears has evolved tremendously over the past decade. Studies from pre-Bethesda era showed usage of a range of formats for reporting. These include descriptive reporting, use of histopathology equivalents, and variably tiered classification systems, ranging from just two categories (non-neoplastic and neoplastic) to four or five categories ([Table 1](#t1-jptm-2017-08-04){ref-type="table"}). In the past and even today in some centers across the country, a range of formats are being used. Histopathology correlates when used are easily interpretable by the clinicians, however, they may not be perfectly applicable to all thyroid aspirates, especially the gray zone lesions: for example, follicular neoplasms, hyperplastic thyroid nodules versus follicular adenoma, papillary hyperplasia versus papillary thyroid carcinoma, or reactive change versus papillary thyroid carcinoma. These cytodiagnostic categories do not provide management guidelines to clinicians. The 2-tier system suffers from similar shortcomings, and can lead to over- as well as under-treatment. A 3- or 4-tiered system has a drawback of inadvertent clubbing of benign and malignant cases. Benign lesions such as hyperplastic nodules and Hashimoto's thyroiditis with nuclear atypia are combined together with follicular/Hurthle cell neoplasms, non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) and carcinomas with poor preservation or less cellularity.

After introduction of the 6-tiered TBSRTC \[[@b5-jptm-2017-08-04]\], several cytopathologists tested its efficacy and reported the ROM in different categories. Pathak *et al*. \[[@b29-jptm-2017-08-04]\] reclassified over 400 thyroid aspirates as per TBSRTC and found strong agreement level among the three observers (Fleiss' kappa score, 50.7) and a significant reduction in the number of inconclusive diagnoses (p \< .001) while using TBSRTC. In another study, TBSRTC was also found to be superior in terms of sensitivity (100% vs 77%) and specificity (82.5% vs 69%) in comparison with the conventional system \[[@b42-jptm-2017-08-04]\]. Upon comparing three thyroid cytology reporting systems, which included conventional (unsatisfactory, benign or negative for malignancy, follicular lesions, indeterminate, positive for malignancy), the British Thyroid Association/the Royal College of Pathologists (BTA/RCP) (Thy 1--Thy 5 categories) and TBSRTC, TBSRTC and BTA/RCP were found to be better in terms of approachability, classification of thyroid lesions, treatment and follow-up than the conventional reporting system \[[@b70-jptm-2017-08-04]\].

NON-DIAGNOSTIC CRITERIA FOR CYTOLOGICAL DIAGNOSIS
=================================================

In cytology, every FNA from any organ system must be evaluated for adequacy in the proper context of clinical and radiological findings. To decrease the false-negative rate, TBSRTC has laid down criteria for adequacy. For accurate interpretation, TBSRTC recommended any thyroid FNA specimen to be considered satisfactory for evaluation when at least six groups of well-preserved, well-stained, and well-visualized follicular cells are seen on the aspirate and each group is composed of at least 10 follicular epithelial cells, preferably on a single slide \[[@b5-jptm-2017-08-04]\]. There are certain exceptions to this rule, such as solid nodules with cytologic atypia, solid nodules with inflammation and colloid nodules. Cyst fluid with less than six groups is considered non-diagnostic/unsatisfactory unless clinical and radiological features are suggestive of a benign cyst \[[@b5-jptm-2017-08-04]\].

Pre-Bethesda era studies considered an FNA as unsatisfactory/non-diagnostic when there was less cellularity (no objective quantification) and when excessive blood or poor technical quality obscured smears such as overtly thick smears and air drying of alcohol-fixed smears. Now, most cytopathologists use objective adequacy criteria laid down by TBSRTC, except for a few who use the Royal College guidelines ([Table 1](#t1-jptm-2017-08-04){ref-type="table"}) \[[@b36-jptm-2017-08-04]\].

Since inception of TBSRTC in 2008, most laboratories in India have adopted it. However, a few studies have used a different set of criteria \[[@b47-jptm-2017-08-04]\]. While TBSRTC requires 5--6 groups of well-preserved follicular epithelial cells with 10 or more cells per group, Tagore *et al*. \[[@b47-jptm-2017-08-04]\] claimed that in case of large clusters of follicular epithelial cells, 10 clusters were needed with each having more than 20 cells. In case of presence of tissue fragments, the minimum number of fragments required was 8 \[[@b47-jptm-2017-08-04]\]. The Royal College of Pathologists (RCP) guidelines were used in one of the studies, which were similar to TBSRTC in terms of cellularity and approach to cystic lesions, i.e., minimum of six groups of follicular cells across all the submitted slides, each with at least 10 well-visualized epithelial cells \[[@b36-jptm-2017-08-04]\]. Samples containing mostly macrophages but lacking enough cells and/or abundant colloid were also considered "unsatisfactory," similar to cases with cellular details obscured by blood/clotting or crushing artifact/poor fixation/poorly spread smears. However, there were others who have just mentioned "blood only/lack of cellularity/poor quality smears/presence of obscuring factors" as the reason for calling a sample unsatisfactory \[[@b15-jptm-2017-08-04],[@b22-jptm-2017-08-04],[@b24-jptm-2017-08-04]\]. Still, some studies have not specified the criteria used for adequacy \[[@b27-jptm-2017-08-04],[@b28-jptm-2017-08-04],[@b57-jptm-2017-08-04]\].

ANCILLARY TECHNIQUES
====================

Of the various ancillary techniques which can be utilized in cytology as diagnostic aid, cell block, immunocytochemistry (ICC) and flow cytometry are probably the most commonly used. Ancillary studies in thyroid cytology are more useful in rare borderline cases of medullary carcinoma \[[@b71-jptm-2017-08-04]\], anaplastic carcinoma \[[@b72-jptm-2017-08-04]\], metastases and lymphomas \[[@b73-jptm-2017-08-04]\], than in the more common papillary thyroid carcinoma. ICC could be used for diagnosing tuberculous thyroiditis, in which Ziehl-Neelsen staining had failed to reveal acid-fast bacilli \[[@b74-jptm-2017-08-04]\]. ICC is a cost-effective and easy technique which can be performed on alcohol or acetone-fixed unstained as well as destained cytology smears and better, if available, on cell blocks \[[@b75-jptm-2017-08-04]-[@b79-jptm-2017-08-04]\]. Nevertheless, its role in differentiating benign from malignant thyroid nodules of follicular cell origin is limited with contradictory results in different studies \[[@b75-jptm-2017-08-04]\].

Cell block is a complementary method of assessing cytology material, which gained importance because of the advantages it has over conventional cytology smears. Cell block is similar to a mini-biopsy, since it imparts better-preserved tissue architecture and provides several sections, which can be utilized to perform a battery of ancillary tests including special stains, immunohistochemistry, ultrastructural studies, and molecular tests \[[@b80-jptm-2017-08-04]\]. Although few studies have shown utility of cell blocks as an adjunct to conventional cytology in diagnosis of thyroid tumors \[[@b81-jptm-2017-08-04]\], their use in everyday clinical practice is limited by their low cellularity, enhanced cost and turnover time \[[@b80-jptm-2017-08-04]\]. As per the available literature, the technique is being done in routine only in rare centers across India \[[@b44-jptm-2017-08-04]\].

Molecular testing for *BRAF* mutation and other molecular alterations, as per American Thyroid Association 2015 guidelines, may be used to supplement malignancy risk assessment, especially in indeterminate cytology \[[@b82-jptm-2017-08-04]\]. However, there is not much published data on the utility of thyroid FNA molecular testing in India. Despite a thorough search, we could find only one abstract, whereby the authors had retrospectively evaluated 40 thyroid aspirate samples for *BRAF* mutation by Sanger sequencing, with effective amplification achieved in over half of them \[[@b83-jptm-2017-08-04]\]. The mutation was detected in 12% of papillary thyroid carcinomas, which was significantly lower than the expected rate \[[@b83-jptm-2017-08-04],[@b84-jptm-2017-08-04]\]. Rare reports of fluorescence *in-situ* hybridization on cytology smears of thyroid are also available \[[@b73-jptm-2017-08-04]\].

While FNAC is the most common primary diagnostic modality for diagnosing follicular-derived thyroid tumors, cases with clinical, cytological or radiological features suggestive of non-follicular cell derived thyroid malignancy are subjected to tru-cut or open biopsy, as it gives the additional advantage of architectural preservation and performing immunohistochemistry. It is of use especially for hematolymphoid neoplasms \[[@b85-jptm-2017-08-04]-[@b88-jptm-2017-08-04]\].

META-ANALYSIS OF THE RISK OF MALIGNANCY IN THE BETHESDA DIAGNOSTIC CATEGORIES
=============================================================================

Owing to the variable number of cases included in various studies, in order to get an accurate overall assessment of the ROM in different categories, a metaanalysis was performed. Of the 52 articles selected for the review, 28 met the inclusion criteria for meta-analysis ([Table 3](#t3-jptm-2017-08-04){ref-type="table"}). It was done using STATA ver. 12.0 (Stata Corp, College Station, TX). Random effects model was used to calculate the pooled estimate. A p \< .05 was considered statistically significant.

TBSRTC has ascribed a particular ROM to every Bethesda category ([Table 3](#t3-jptm-2017-08-04){ref-type="table"}). Meta-analysis revealed a higher ROM for the category III as compared to TBSRTC estimates, 34% versus 5%-- 15% ([Figs. 1](#f1-jptm-2017-08-04){ref-type="fig"}--[](#f2-jptm-2017-08-04){ref-type="fig"}[](#f3-jptm-2017-08-04){ref-type="fig"}[](#f4-jptm-2017-08-04){ref-type="fig"}[](#f5-jptm-2017-08-04){ref-type="fig"}[6](#f6-jptm-2017-08-04){ref-type="fig"}). Recent meta-analyses by Straccia *et al*. \[[@b89-jptm-2017-08-04]\] and Krauss *et al*. \[[@b6-jptm-2017-08-04]\] also found a high ROM (27% and 24%, respectively) for category III. Interestingly, we have also found a ROM of 34.3% (unpublished data) at our institute. Category III includes cases which are neither undoubtedly benign nor can be categorized into higher categories of IV and higher. It is so heterogeneous that sub-classification of AUS/FLUS has been recommended by some authors, based on the presence of architectural and/or nuclear atypia, improving cancer risk estimation \[[@b90-jptm-2017-08-04]-[@b93-jptm-2017-08-04]\]. Although TBSRTC defines AUS/FLUS category as last resource category and should only be ≤ 7% of total thyroid FNAs, it was found out to be a heterogeneous category which ranged from \< 1% to \> 5% in different studies ([Table 2](#t2-jptm-2017-08-04){ref-type="table"}). We have an approximately 11% rate of AUS/FLUS category in our institute (unpublished data).

Cases with poor cellularity and/or technical quality having some atypia are also huddled into this category. Our institute is a teaching hospital, where aspiration is performed by residents. Hence, lack of adequate experience of the aspirator results in hemodilution and poor smear preparation and may contribute to a higher ROM of category III. Re-aspirating such cases along with radiological correlation, to some extent, decreases the proportion of cases in this category as well as the ROM. Category I also had a higher ROM and may be explained by the same reason.

Impact of the recent reclassification of non-invasive encapsulated follicular variant of papillary carcinoma of thyroid into NIFTP is not evident in this review as most studies included are from pre-NIFTP era. Studies post-NIFTP introduction have not specified it in their histopathological diagnoses. It is likely that the impact, particularly a decrease of ROM for the indeterminate diagnostic categories \[[@b94-jptm-2017-08-04]\], is dependent on the incidence of NIFTP, which is relatively low in our settings (unpublished data), consistent with Asian data \[[@b95-jptm-2017-08-04]\].

In addition, a wide 95% confidence interval (CI) was noted for categories III (23%--45%), IV (15%--36%), and V (55%--84%). The wide range may be attributed to interobserver variation and differences in experience levels of the pathologists. As the extreme entities (benign and malignant) are the easiest to categorize in a well-prepared aspirate, the CI values in the two categories were low. Krauss *et al*. \[[@b6-jptm-2017-08-04]\] in their recent meta-analysis also reported a wide CI for categories III, IV, and V. The authors ascribed it to subjective differences in the interpretation of the Bethesda criteria for diagnosis of these categories, and recommended introduction of a performance measure such as ratio of AUS/FLUS to total thyroid FNAs for each laboratory to follow. As expected, RON which includes benign tumors (the most common being follicular adenoma) was higher than the ROM ([Table 3](#t3-jptm-2017-08-04){ref-type="table"}).

CONCLUSION
==========

Thyroid FNAC is practiced all over India in academic and private institutes as well as private hospitals and laboratories. In India, most thyroid aspiration samples are collected by pathologists, using manual palpation. Most centers prepare both alcohol-fixed and air-dried smears stained with Papanicolaou/H&E and May-Grünwald-Giemsa, respectively. TBSRTC is currently the most widely used reporting system with different studies showing good efficacy and interobserver concordance. Ancillary studies including core biopsy and molecular testing, as of now, have limited applicability and acceptability in thyroid cytology in India. Category III is the most heterogeneous category with a wide range of ROM and RON. Case to case discussion among the clinicians and pathologists supplemented by radiological correlation may help improve the management of these patients.
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![Forest plot of meta-analysis on the risk of malignancy for Bethesda category VI (malignant)\[[@b13-jptm-2017-08-04]-[@b17-jptm-2017-08-04],[@b21-jptm-2017-08-04],[@b23-jptm-2017-08-04],[@b30-jptm-2017-08-04]-[@b36-jptm-2017-08-04],[@b38-jptm-2017-08-04],[@b42-jptm-2017-08-04],[@b44-jptm-2017-08-04],[@b45-jptm-2017-08-04],[@b46-jptm-2017-08-04],[@b49-jptm-2017-08-04],[@b50-jptm-2017-08-04],[@b52-jptm-2017-08-04]-[@b54-jptm-2017-08-04],[@b56-jptm-2017-08-04],[@b60-jptm-2017-08-04],[@b61-jptm-2017-08-04],[@b63-jptm-2017-08-04]\].](jptm-2017-08-04f6){#f6-jptm-2017-08-04}

###### 

Review of the published studies on thyroid FNA in India

  No.   Study                                                                                                 Place               Needle size and technique                                                                              Wet fixation                       Staining technique used   Reporting system followed   
  ----- ----------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------- ------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------
  1     Mandreker *et al*. (1995) \[[@b13-jptm-2017-08-04]\]                                                  Goa                 n/s                                                                                                    n/s                                n/s                                                   Unsatisfactory, benign, SFM, malignant
  2     Sirpal (1996) \[[@b14-jptm-2017-08-04]\]                                                              Delhi               21G                                                                                                    n/s                                Pap, H&E                  Leishman-Giemsa             Malignant, non-neoplastic, FN, Hurthle cell tumors, thyroglossal cyst, extrathyroidal, inconclusive when unsatisfactory
  3     Handa *et al*. (2008) \[[@b15-jptm-2017-08-04]\]                                                      Chandigarh          23G ± aspiration, manual^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                              n/s                                Pap, H&E                  MGG                         n/s
  4     Guhamallick *et al*. (2008) \[[@b16-jptm-2017-08-04]\]                                                Kolkata             23--24G + aspiration                                                                                   n/s                                Pap, H&E                  Leishman-Giemsa             Unsatisfactory, non-neoplastic, indeterminate, malignant
  5     Gupta *et al*. (2010) \[[@b17-jptm-2017-08-04]\]                                                      Jammu and Kashmir   n/s                                                                                                    Ether-95% alcohol solution         Pap                       n/s                         Benign, FN, SFM, malignant
  6     Bagga and Mahajan (2010) \[[@b18-jptm-2017-08-04]\]                                                   Haryana             23--25G, non-aspiration^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                               95% Ethanol                        H&E                       MGG                         Unsatisfactory, benign, SFM, malignant
  7     Sengupta *et al*. (2011) \[[@b19-jptm-2017-08-04]\]                                                   Bihar               22--23G + aspiration^[b](#tfn2-jptm-2017-08-04){ref-type="table-fn"}^                                  n/s                                n/s                       MGG                         Colloid goiter, granulomatous thyroiditis, FA, FC, anaplastic carcinoma
  8     Renuka *et al*. (2012) \[[@b20-jptm-2017-08-04]\]                                                     Andhra Pradesh      22G ± aspiration, USG in some                                                                          95% Methanol                       Pap, H&E                  MGG                         TBSRTC
  9     Sharma and Mathur (2012) \[[@b21-jptm-2017-08-04]\]                                                   Rajasthan           23G + aspiration                                                                                       Ether-95% alcohol solution         Pap, H&E                  Giemsa                      Unsatisfactory, non-neoplastic, FN, SFM, malignant (RCP)
  10    Patel *et al*. (2013) \[[@b22-jptm-2017-08-04]\]                                                      Gujarat             23--24G ± aspiration^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                                  95% Ethanol                        Pap, H&E                  MGG                         Non-neoplastic, neoplastic, others
  11    Mondal *et al*. (2013) \[[@b23-jptm-2017-08-04]\]                                                     West Bengal         n/s, USG in some^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                                      n/s                                Pap                       Leishman-Giemsa             TBSTRC
  12    Kukar *et al*. (2013) \[[@b24-jptm-2017-08-04]\]                                                      Punjab              n/s^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                                                   95% isopropanol                    Pap, H&E                  MGG                         Non-neoplastic, neoplastic
  13    Bhasin *et al*. (2013) \[[@b25-jptm-2017-08-04]\]                                                     Punjab              n/s                                                                                                    n/s                                n/s; MGG as per figures                               TBSRTC
  14    Borgohain *et al*. (2014) \[[@b26-jptm-2017-08-04]\]                                                  Assam               n/s                                                                                                    n/s                                n/s                       MGG                         Non-neoplastic, neoplastic
  15    Mangshetty *et al*. (2014) \[[@b27-jptm-2017-08-04]\]                                                 Karnataka           22--24G + aspiration                                                                                   Alcohol                            Pap                       MGG                         Unsatisfactory, benign, malignant
  16    Panchal *et al*. (2014) \[[@b28-jptm-2017-08-04]\]                                                    Maharashtra         22/23G + aspiration                                                                                    95% Ethanol                        Pap                       n/s                         Unsatisfactory, benign, SFM, malignant
  17    Pathak *et al*. (2014) \[[@b29-jptm-2017-08-04]\]                                                     Delhi               n/s                                                                                                    n/s                                Pap                       MGG                         TBSRTC
  18    Sukumaran *et al*. (2014) \[[@b30-jptm-2017-08-04]\]                                                  Kerala              n/s                                                                                                    95% alcohol                        Pap                       n/s                         TBSRTC
  19    Arul and Masilamani (2015) \[[@b31-jptm-2017-08-04]\]                                                 Tamil Nadu          n/s                                                                                                    n/s                                n/s, H&E as per figures                               TBSRTC
  20    Arul *et al*. (2015) \[[@b32-jptm-2017-08-04]\]                                                       Tamil Nadu          n/s, USG if small lesion^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                              n/s                                H&E                       MGG                         TBSRTC
  21    Sekhar *et al*. (2015) \[[@b33-jptm-2017-08-04]\]                                                     Karnataka           23--24G + aspiration                                                                                   95% Ethanol                        Pap, H&E                  MGG                         TBSRTC
  22    Mehra and Verma (2015) \[[@b34-jptm-2017-08-04]\]                                                     Delhi               n/s, USG in all                                                                                        n/s                                Pap                       MGG                         TBSRTC
  23    Agrawal *et al*. (2015) \[[@b35-jptm-2017-08-04]\]                                                    Uttar Pradesh       23G + aspiration                                                                                       95% Ethanol                        Pap, H&E                  MGG                         TBSRTC
  24    Sharma (2015) \[[@b36-jptm-2017-08-04]\]                                                              Tamil Nadu          n/s, manual                                                                                            n/s                                n/s                                                   Unsatisfactory, benign, follicular pattern lesions, suspicious (includes atypical), malignant
  25    Thakkar *et al*. (2015) \[[@b37-jptm-2017-08-04]\]                                                    Gujarat             22/24G + aspiration^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                                   n/s                                H&E                       MGG                         TBSRTC
  26    Garg *et al*. (2015) \[[@b38-jptm-2017-08-04]\]                                                       Gujarat             23--24G + aspiration^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                                  n/s                                n/s                                                   TBSRTC
  27    Kathirvel (2015) \[[@b39-jptm-2017-08-04]\]                                                           Tamil Nadu          25--27G                                                                                                100% Isopropanol                   H&E                                                   TBSRTC
  28    Alagarsamy *et al*. (2015) \[[@b40-jptm-2017-08-04]\]                                                 Tamil Nadu          23G ± aspiration                                                                                       100% Isopropanol                   H&E                       n/s                         Colloid goiter, adenoma, carcinoma, others
  29    Mamatha *et al*. (2015) \[[@b42-jptm-2017-08-04]\]                                                    Telangana           n/s                                                                                                    n/s                                n/s                       n/s                         Unsatisfactory, colloid cyst/goiter, follicular lesions/ neoplasm, indeterminate, SFM, malignant as well as TBSRTC
  30    Gupta *et al*. (2015) \[[@b43-jptm-2017-08-04]\]                                                      Uttar Pradesh       n/s                                                                                                    n/s                                Pap                       Diff-Quick                  Histopathological equivalents as well as TBSRTC
  31    Hathila *et al*. (2016) \[[@b41-jptm-2017-08-04]\]                                                    Gujarat             23G, non-aspiration                                                                                    95% Ethanol                        Pap, H&E                  MGG                         Benign, malignant
  32    Shankar *et al*. (2016) \[[@b44-jptm-2017-08-04]\]                                                    Tamil Nadu          n/s + aspiration                                                                                       n/s                                Pap                       n/s                         TBSRTC
  33    Prathima *et al*. (2016) \[[@b45-jptm-2017-08-04]\]                                                   Karnataka           n/s, USG in some                                                                                       Alcohol                            Pap, H&E                  Giemsa                      TBSRTC
  34    Mehrotra *et al*. (2016) \[[@b46-jptm-2017-08-04]\]                                                   Karnataka           n/s ± aspiration, USG in some                                                                          95% Ethanol                        H&E                       MGG                         TBSRTC
  35    Tagore *et al*. (2016) \[[@b47-jptm-2017-08-04]\]                                                     Karnataka           22G + aspiration                                                                                       Alcohol                            Pap                       MGG                         TBSRTC
  36    Kalita and Das (2016) \[[@b48-jptm-2017-08-04]\]                                                      Assam               23G ± aspiration                                                                                       n/s                                n/s                       MGG                         TBSRTC
  37    Bhartiya *et al*. (2016) \[[@b49-jptm-2017-08-04]\]                                                   Bihar               23--24G + aspiration, USG in some^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"}^                     Wet fixed                          Pap                       Leishman-Giemsa             TBSRTC
  38    Kulkarni *et al*. (2016) \[[@b50-jptm-2017-08-04]\]                                                   Madhya Pradesh      n/s                                                                                                    n/s                                Pap                       n/s                         TBSRTC
  39    Lohiya *et al*. (2016) \[[@b51-jptm-2017-08-04]\]                                                     Rajasthan           23/24G                                                                                                 n/s                                n/s                       MGG                         TBSRTC
  40    Kasliwal *et al*. (2016) \[[@b52-jptm-2017-08-04]\]                                                                       24--26G + aspiration                                                                                   95% Ethanol                        H&E                       MGG                         TBSRTC
  41    Khatib *et al*. (2016) \[[@b53-jptm-2017-08-04]\]                                                     Maharashtra         n/s, USG if unsatisfactory                                                                             n/s                                Pap                       Giemsa                      TBSRTC
  42    Pantola *et al*. (2016) \[[@b54-jptm-2017-08-04]\]                                                    Tamil Nadu          23G                                                                                                    95% Alcohol                        Pap, H&E                  MGG                         TBSRTC
  43    Babu *et al*. (2016) \[[@b55-jptm-2017-08-04]\]                                                       Tamil Nadu          23G                                                                                                    Ether-95% alcohol solution         Pap                       n/s                         Unsatisfactory, benign, malignant
  44    Solanki *et al*. (2016) \[[@b56-jptm-2017-08-04]\]                                                    Rajasthan           n/s                                                                                                    n/s                                H&E                       MGG                         TBSRTC
  45    Aramani and Gururajaprasad (2017) \[[@b57-jptm-2017-08-04]\]                                          Karnataka           24--25G + aspiration                                                                                   95% Ethanol                        Pap, H&E                  MGG                         Benign, malignant
  46    Sunder and Khan (2017) \[[@b58-jptm-2017-08-04]\],^[b](#tfn2-jptm-2017-08-04){ref-type="table-fn"}^   Telangana           23/25/26G + aspiration                                                                                 95% Ethyl alcohol or isopropanol   Pap, H&E                  MGG                         Benign, malignant
  47    Garg *et al*. (2017) \[[@b59-jptm-2017-08-04]\]                                                       Maharashtra         n/s ± aspiration, USG in all                                                                           n/s                                Pap                       MGG                         TBSRTC
  48    Kannan *et al*. (2017) \[[@b60-jptm-2017-08-04]\]                                                     Karnataka           n/s^[a](#tfn1-jptm-2017-08-04){ref-type="table-fn"},[b](#tfn2-jptm-2017-08-04){ref-type="table-fn"}^   n/s                                n/s                       n/s                         TBSRTC
  49    Mahajan *et al*. (2017) \[[@b61-jptm-2017-08-04]\]                                                    Chandigarh          n/s                                                                                                    n/s                                n/s                       n/s                         TBSRTC
  50    Chandra *et al*. (2017) \[[@b62-jptm-2017-08-04]\]                                                    Uttarakhand         26--28G                                                                                                Alcohol                            Pap, H&E                  MGG                         TBSRTC
  51    Laishram *et al*. (2017) \[[@b63-jptm-2017-08-04]\]                                                   Manipur             n/s                                                                                                    n/s                                n/s                       MGG                         TBSRTC

FNA, fine needle aspiration; n/s, not specified; SFM, suspicious for malignancy; Pap, Papanicolaou stain; H&E, hematoxylin and eosin; FN, follicular neoplasm; MGG, May-Grünwald-Giemsa; FA, follicular adenoma; FC, follicular carcinoma; USG, ultrasound-guided aspirate; TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; RCP, Royal College of Pathologists guidelines.

FNA performed by cytopathologist;

FNA performed by clinician.

###### 

Descriptive data with the risk of malignancy

  No.   Study                                                    Thyroid FNA (operated nodules)                                 Distribution of the Bethesda categories and corresponding risk of malignancy (%)                                                                                                                                                       
  ----- -------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------- ------------------------------------------------------------ ------------- ---------------------------------------------------------- ------------------------------------------------------------
  1     Mandreker *et al*. (1995) \[[@b13-jptm-2017-08-04]\]     1,992 (238)                                                    12.7                                                                               78.2 (5.5)    \-                                                           \-            7.6 (26.3)                                                 1.5 (91.7)
  2     Sirpal (1996) \[[@b14-jptm-2017-08-04]\]                 1,114^[a](#tfn3-jptm-2017-08-04){ref-type="table-fn"}^ (128)   0.6^[b](#tfn4-jptm-2017-08-04){ref-type="table-fn"}^ (0)                           97.1 (0)      \-                                                           1 (11.1)      \-                                                         1.3 (100)
  3     Handa *et al*. (2008) \[[@b15-jptm-2017-08-04]\]         434 (66)                                                       5.1                                                                                87.8 (1.9)    \-                                                           3.2 (0)       \-                                                         3.9 (100)
  4     Guhamallick *et al*. (2008) \[[@b16-jptm-2017-08-04]\]   288 (75)                                                       13.5                                                                               68.4 (3.1)    \-                                                           9.4 (30)      \-                                                         8.7 (95.6)
  5     Gupta *et al*. (2010) \[[@b17-jptm-2017-08-04]\]         75 (75)                                                        \-                                                                                 60 (6.7)      \-                                                           24 (16.7)     4 (0)                                                      12 (100)
  6     Bagga and Mahajan (2010) \[[@b18-jptm-2017-08-04]\]      252 (32)                                                       1.6                                                                                90.5          \-                                                           \-            6.7                                                        1.2
  7     Renuka *et al*. (2012) \[[@b20-jptm-2017-08-04]\]        564                                                            17                                                                                 70.5          1.9                                                          4.2           2.6                                                        3.5
  8     Sharma and Mathur (2012) \[[@b21-jptm-2017-08-04]\]      94 (76)                                                        2.1                                                                                53.2 (0)      \-                                                           35.1 (10)     2.1 (100)                                                  7.4 (100)
  9     Mondal *et al*. (2013) \[[@b23-jptm-2017-08-04]\]        1,020 (323)                                                    1.2 (0)                                                                            87.5 (4.5)    1 (20)                                                       4.2 (30.6)    1.4 (75)                                                   4.7 (97.8)
  10    Bhasin *et al*. (2013) \[[@b25-jptm-2017-08-04]\]        80                                                             1.2                                                                                61.2          10                                                           20            3.8                                                        3.8
  11    Panchal *et al*. (2014) \[[@b28-jptm-2017-08-04]\]       300 (36)                                                       \-                                                                                 98.7          \-                                                           \-            0.3                                                        1
  12    Pathak *et al*. (2014) \[[@b29-jptm-2017-08-04]\]        454                                                            25.7                                                                               59            6                                                            4             1.8                                                        3.5
  13    Sukumaran *et al*. (2014) \[[@b30-jptm-2017-08-04]\]     248 (248)                                                      6 (6.7)                                                                            12.5 (12.9)   4.4 (54.6)                                                   13.3 (87.9)   4 (100)                                                    59.7 (100)
  14    Arul and Masilamani (2015) \[[@b31-jptm-2017-08-04]\]    483 (209)                                                      5 (8.3)                                                                            44.5 (1.1)    2.9 (0)                                                      21.5 (11.5)   15.3 (96.9)                                                10.8 (100)
  15    Arul *et al*. (2015) \[[@b32-jptm-2017-08-04]\]          603 (392)                                                      2.7 (0)                                                                            65.2 (1.2)    10 (24.4)                                                    10.6 (28.9)   5.3 (70.8)                                                 6.3 (100)
  16    Sekhar *et al*. (2015) \[[@b33-jptm-2017-08-04]\]        150 (64)                                                       2.6 (0)                                                                            76.6 (0)      0.7                                                          12.7 (5.9)    2.7 (100)                                                  4.7 (66.7)
  17    Mehra and Verma (2015) \[[@b34-jptm-2017-08-04]\]        225 (40)                                                       7.2 (0)                                                                            80 (13)       4.9 (100)^[c](#tfn5-jptm-2017-08-04){ref-type="table-fn"}^   2.2 (25)      3.5 (50)                                                   2.2 (100)
  18    Agrawal *et al*. (2015) \[[@b35-jptm-2017-08-04]\]       281 (134)                                                      2.5 (0)                                                                            87.9 (1.8)    3.9                                                          2.5 (18.2)    1.8 (80)                                                   1.4 (100)
  19    Sharma (2015) \[[@b36-jptm-2017-08-04]\]                 724 (724)                                                      \-                                                                                 87.7 (1.3)    \-                                                           \-            2.9 (52.4)                                                 9.4 (97.1)
  20    Thakkar *et al*. (2015) \[[@b37-jptm-2017-08-04]\]       134 (24)                                                       4.5 (0)                                                                            85.8 (0)      0.7                                                          7.5 (33.3)    0.7                                                        0.7
  21    Garg *et al*. (2015) \[[@b38-jptm-2017-08-04]\]          100 (60)                                                       6 (20)                                                                             78 (0)        4 (25)                                                       5 (20)        3 (66.7)                                                   4 (100)
  22    Kathirvel (2015) \[[@b39-jptm-2017-08-04]\]              59                                                             15.3                                                                               16.9          15.3                                                         16.9          15.3                                                       20.3
  23    Mamatha *et al*. (2015) \[[@b42-jptm-2017-08-04]\]       240 (214)                                                      10.8                                                                               59.2 (0)      4.2 (50)                                                     15 (6.7)      4.2 (60)                                                   6.6 (100)
  24    Gupta *et al*. (2015) \[[@b43-jptm-2017-08-04]\]         300                                                            11                                                                                 78            2                                                            3             1                                                          5
  25    Shankar *et al*. (2016) \[[@b44-jptm-2017-08-04]\]       402 (92)                                                       10.7 (0)                                                                           81.6 (1.6)    1.2 (0)                                                      1.7 (28.6)    2 (71.4)                                                   2.7 (80)
  26    Prathima *et al*. (2016) \[[@b45-jptm-2017-08-04]\]      178 (60)                                                       11.7 (33.3)                                                                        77.5 (7.1)    1.1 (50)                                                     3.9 (25)      2.2 (66.7)                                                 3.3 (100)
  27    Mehrotra *et al*. (2016) \[[@b46-jptm-2017-08-04]\]      175 (34)                                                       4.6                                                                                68.6 (0)      5.7                                                          17.1 (0)      1.1^[c](#tfn5-jptm-2017-08-04){ref-type="table-fn"}^ (0)   2.9^[c](#tfn5-jptm-2017-08-04){ref-type="table-fn"}^ (100)
  28    Tagore *et al*. (2016) \[[@b47-jptm-2017-08-04]\]        100                                                            3                                                                                  81            0                                                            9             3                                                          4
  29    Kalita and Das (2016) \[[@b48-jptm-2017-08-04]\]         664                                                            12                                                                                 72.3          1.8                                                          4.8           1.5                                                        7.5
  30    Bhartiya *et al*. (2016) \[[@b49-jptm-2017-08-04]\]      238 (105)                                                      5.9                                                                                84 (2)        1.3                                                          2.9 (0)       2.5                                                        3.4 (100)
  31    Kulkarni *et al*. (2016) \[[@b50-jptm-2017-08-04]\]      151 (16)                                                       11.2 (0)                                                                           76.8 (0)      0                                                            9.3 (25)      0.7                                                        2 (100)
  32    Lohiya *et al*. (2016) \[[@b51-jptm-2017-08-04]\]        250                                                            4                                                                                  88            2                                                            1.6           0.8                                                        3.6
  33    Kasliwal *et al*. (2016) \[[@b52-jptm-2017-08-04]\]      411 (97)                                                       0.5                                                                                94.2 (2.6)    0                                                            3.5 (22.2)    0                                                          1.7 (100)
  34    Khatib *et al*. (2016) \[[@b53-jptm-2017-08-04]\]        287 (287)                                                      0.7 (0)                                                                            87.8 (3.3)    3.5 (20)                                                     4.2 (25)      1.7 (80)                                                   2.1 (100)
  35    Pantola *et al*. (2016) \[[@b54-jptm-2017-08-04]\]       218 (44)                                                       5.5 (0)                                                                            69.3 (0)      10.5 (8.3)                                                   8.2 (10)      2.3 (100)                                                  4.1 (100)
  36    Solanki *et al*. (2016) \[[@b56-jptm-2017-08-04]\]       1,287 (62)                                                     22 (18.2)                                                                          73.9 (2.6)    0.7 (0)                                                      1.5 (50)      0.4 (50)                                                   1.3 (100)
  37    Kannan *et al*. (2017) \[[@b60-jptm-2017-08-04]\]        404 (243)                                                      7.7 (28.6)                                                                         40.8 (13)     24.3 (41.7)                                                  10.6 (46.9)   6.9 (96.3)                                                 9.7 (100)
  38    Mahajan *et al*. (2017) \[[@b61-jptm-2017-08-04]\]       4,532 (335)                                                    3.5 (50)                                                                           79.6 (7.8)    2.5 (50)                                                     3.9 (23.6)    0.5 (75)                                                   9.8 (85.4)
  39    Chandra *et al*. (2017) \[[@b62-jptm-2017-08-04]\]       971^[d](#tfn6-jptm-2017-08-04){ref-type="table-fn"}^           5.5                                                                                74.9          6.4 (51.4)                                                   2.6           3.2                                                        7
  40    Laishram *et al*. (2017) \[[@b63-jptm-2017-08-04]\]      576 (11)                                                       5.2                                                                                89.9          0                                                            2.2 (40)      0.3                                                        2.2 (100)

FNA, fine-needle aspiration.

Excluding nine extrathyroidal;

After adjustment of "inconclusive" to the Bethesda terminology;

Only one case with available histology;

Included 35 cases of category III with surgical follow-up.

###### 

Summary of meta-analysis

  Category   ROM   RON                                                           
  ---------- ----- ------------- ------ ----- -------- ---- ------------- ------ -----
  I          18    15 (6--24)    11.8   .34   1--4     15   34 (17--52)   65.5   .01
  II         28    3 (2--4)      54     .00   0--3     23   8 (6--10)     80.3   .00
  III        15    34 (23--45)   57.9   .01   5--15    11   62 (44--81)   77.4   .00
  IV         27    26 (15--36)   87.2   .00   15--30   23   81 (73--89)   77.2   .00
  V          21    69 (55--84)   87.7   .00   60--75   17   76 (62--90)   64.1   .00
  VI         28    94 (89--98)   56.3   .03   97--99   24   95 (90--99)   58.1   .05

ROM, risk of malignancy; CI, confidence interval; TBSRTC, the Bethesda System for Reporting Thyroid Cytopathology; RON, risk of neoplasia.
